Outcomes of Acute Coronary Syndrome in a Large Canadian Cohort: Impact of Chronic Renal Insufficiency, Cardiac Interventions, and Anemia

Therapeutic Management in Patients with Renal Failure who Experience an Acute Coronary Syndrome

“…We used baseline creatinine to estimate chronic CrC and GFR. However, our approach was similar to that used in other studies (8,11) and seems a reasonable option, given that measurements were performed on admission, before any procedure could lead to increased creatinine levels. Lipid profile measurements, information on drugs taken by patients but unrelated to cardiac management, and the type of lipid-lowering agent used were not recorded, which does not allow us to make a clear statement on the appropriateness of lipid management in patients with renal failure.…”

“…Only one previous report (11) has shown lower use of LLDs in patients with CKD after an ACS. In our study, CrC was independently associated with use of LLDs at discharge.…”

“…Most previous reports recruited patients who experienced ACS in the mid-1990s, whereas a secular trend toward increased use of cardioprotective drugs has been demonstrated in recent years (12,13). Previous work on the topic has often come from large registries that may lack clinical information on some comorbidities and concomitant therapies (10,11).…”

“…In patients who are discharged from the hospital after an acute coronary syndrome (ACS), the use of cardioprotective drugs seems to vary according to the level of kidney function. Generally, studies report lower use of aspirin (8,9,11), ␤-blockers (8,9,11), and lipidlowering drugs (LLDs) (11) at discharge in patients with CKD. The mechanisms underlying these reported differences are unclear at the present time.…”

Combination of coronary heart disease, chronic heart failure, and anaemic syndrome: clinical features and prognostic impact of anaemia treatment

“…В таких случаях чаще всего отмечается ухудшение прогноза как острых, так и хронических форм ИБС, прогрессирование ХПН [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27].Кроме того, некоторые исследователи предста-вили данные о том, что принимаемое за анемию при ИБС патологическое состояние является не анемией как таковой, а проявлением гемодилюции, характер-ной для ХСН [28][29][30].Хотелось бы также отметить, что, несмотря на обилие работ, посвященных изучению течения и прогноза ИБС и ХСН при анемии [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27], до последнего времени было крайне мало работ о влиянии коррекции анемии на течение и прогноз ИБС [31][32][33][34][35]…”